A large meta-analysis reveals that most antipsychotics achieve near-maximal efficacy at the lower end of recommended dose ranges, typically around 3-5 mg/d of risperidone equivalents.
The development of robust clinical trial methodologies increasingly relies on advanced statistical frameworks for model selection and the characterisation of dose–response relationships. With modern ...
Clinical Trials Arena on MSN
Sensorion reports six-month Audiogene trial results for gene therapy
All six participants tolerated surgical and intra-cochlear SENS-501 administration well, with no serious adverse events ...
Results validate dose selection and de-risk pivotal trial in US and Europe clinical development program ...
CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating ...
Creating a Proxy for Baseline Eastern Cooperative Oncology Group Performance Status in Electronic Health Records for Comparative Effectiveness Research in Advanced Non–Small Cell Lung Cancer ...
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the ...
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological ...
CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...
Researchers reported positive results for a novel agent for dermatomyositis from a phase 3 trial today at the 2026 American Academy of Dermatology Annual Meeting in Denver. The results were published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results